Almost half of patients hospitalised for acute heart failure in Europe are readmitted within a year, according to a new study led by researchers at Karolinska Institutet and published in the European Heart Journal. The risk of death also remains high, especially for those with more severely reduced heart function.

The COVID-19 pandemic was a major health crisis that challenged citizens’ information management routines. Epistemic ideals guided how people scanned and filtered information, engaged with it and adapted their behaviour accordingly. Conducted in Finland, a recent study found that four distinctive profiles characterise citizens’ engagement with information. 

What if people could stay healthier, stronger, and mentally sharper as they grow older—not by treating diseases one by one but by slowing a biological process that drives aging itself? A new University of Rochester–led research effort will test whether a drug originally developed to treat HIV can quiet a chronic immune response triggered by the body’s own DNA, to help preserve overall health and function later in life. The project is supported by a contract of up to $22 million over five years from the Advanced Research Projects Agency for Health (ARPA-H) and includes collaborators from Brown University, University of Connecticut, The University of Texas Medical Branch, University of Texas Health Houston, University of Nebraska, and Transposon Therapeutics.